CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Omicron variant boosts vaccine maker stocks MRNA and BTNX

By Robert Davis

17:01, 29 November 2021

Coronavirus vaccines on the production line
Moderna and BioNTech shares gain – Photo: Mike Mareen via Shutterstock

The new Covid-19 Omicron variant boosted the stocks of some vaccine manufacturers on Monday.

Moderna’s stock opened at $370.33 (£277.58) per share before settling down to $359.42 by 15:00 UTC, representing a 9% gain on the day.

Similarly, BioNTech saw its stock open at $369.50 before settling at $360.79, a 3.5% gain from its previous close.

Pfizer and Johnson & Johnson (J&J) both had negligible gains on Monday as well. Pfizer’s stock opened Monday near its 52-week high at $55.15 before falling to $54.26 by mid-day. Similarly, J&J’s stock was up 0.24% to $159.68.

Merck and Novavax were the only manufacturers to see their stock lose value. Merck dropped 4.47% to $75.62 while Novavax opened higher at $228.76 before settling at $215.37, a loss of more than 1% from its previous close.

Addressing mutations

The stocks that saw the greatest upward movement on Monday all have one thing in common: their vaccine products can be quickly edited to address the Omicron variant and future mutations, according to the companies’ executives.

Moderna’s CEO Stéphane Bancel released a three-point plan to address the new variant over the weekend. The Massachusetts-based company is already testing a booster shot for other Covid-19 strains and plans to have a Omicron booster ready by early 2022.

Similarly, Albert Bourla, Pfizer’s CEO, told CNBC’s “Squawk Box” on Monday that Pfizer’s Covid pill was designed with new variants in mind, saying definitively that “our oral treatment will not be affected by this virus.”

TSLA

237.41 Price
+1.320% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.12

AMZN

146.58 Price
+0.580% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.13

COIN

131.92 Price
+6.140% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.27

GME

15.58 Price
+7.870% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.13

BioNTech’s stock also saw a boost from Pfizer’s plans to adapt its oral pill to combat the Omicron variant.

What is your sentiment on PFE?

29.26
Bullish
or
Bearish
Vote to see Traders sentiment!

Drug pipeline problems

Other manufacturers like Merck weren’t so lucky. Analysts said their drug development pipelines could negatively impact their Covid-19 treatment production.

For example, Citi Group downgraded the stock from “buy” to “neutral” on Monday with a price target between $85 and $105 per share.

Analyst Andrew Baum wrote in his note that the company’s cancer-fighting drugs could complicate its Covid-19 pill development.

“We expect the diminishing outlook for islatravir to further expedite Merck’s business development efforts,” he wrote.

Similarly, Morgan Stanley lowered its price target for the stock to between $85 and $82 while rating the stock at “equal weight.”

Read more: Covid chaos, Black Friday supply issues

Markets in this article

BNTX
BioNtech SE (Extended Hours)
97.46 USD
-2.75 -2.750%
BNTX
BioNtech SE (Extended Hours)
97.46 USD
-2.75 -2.750%
JNJ
Johnson & Johnson (Extended Hours)
155.95 USD
2.15 +1.400%
JNJ
Johnson & Johnson (Extended Hours)
155.95 USD
2.15 +1.400%
MRNA
Moderna Inc (Extended Hours)
79.39 USD
1.57 +2.030%

Related topics

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading